S&P7,747.7+1.06%

Nasdaq29,482.3+1.16%Stoxx6,382.6+0.32%FTSE10,831.5+0.70%Nikkei64,796.3+0.91%Hang Seng25,752.9+2.14%DXY99.00+0.01%EUR/USD1.1627+0.36%USD/JPY156.38−1.60%GBP/USD1.3527+0.32%Gold4,519.1+0.61%Silver67.37+0.59%WTI91.95+0.71%Brent95.89+0.39%10Y4.76%−3 bpVIX14.32−5.79%S&P7,747.7+1.06%Nasdaq29,482.3+1.16%Stoxx6,382.6+0.32%FTSE10,831.5+0.70%Nikkei64,796.3+0.91%Hang Seng25,752.9+2.14%DXY99.00+0.01%EUR/USD1.1627+0.36%USD/JPY156.38−1.60%GBP/USD1.3527+0.32%Gold4,519.1+0.61%Silver67.37+0.59%WTI91.95+0.71%Brent95.89+0.39%10Y4.76%−3 bpVIX14.32−5.79%S&P7,747.7+1.06%

Hypotheses · Open · Decides 31 Dec 2026 · The waste has to go somewhere

Foundayo is a named line

A Lilly quarter discloses Foundayo as a named revenue line, or a prescription run-rate in a filing, by 31 Dec 2026.

X LinkedIn Email

Resolves by: 31 Dec 2026
Confirm: The pill was a product.
Kill: An approval, not a cluster.

Grade

Open. Resolves by 31 Dec 2026. Blocked: series not wired; grades by the published desk rule when the source publishes.

Related writing

No article rides on this one yet.